Gastric peroral endoscopic myotomy for management of refractory gastroparesis in patients with gastric neurostimulator devices: a multicenter retrospective case control study
Gastric neurostimulation (GNS) and gastric peroral myotomy (G-POEM), therapies for refractory gastroparesis, are associated with suboptimal outcomes. We studied the role of G-POEM as a salvage therapy in patients with refractory symptoms after GNS implantation. This was a multicenter, retrospective,...
Gespeichert in:
Veröffentlicht in: | Gastrointestinal endoscopy 2023-10, Vol.98 (4), p.559-566.e1 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 566.e1 |
---|---|
container_issue | 4 |
container_start_page | 559 |
container_title | Gastrointestinal endoscopy |
container_volume | 98 |
creator | Ichkhanian, Yervant Al-Haddad, Mohammad A. Jacobs, Chelsea C. Schlachterman, Alexander Yang, Juliana Canakis, Andrew Kim, Raymond Guerson-Gil, Arcelia D’Souza, Lionel S. Alsheik, Eva Ginnebaugh, Brian D. Khashab, Mouen A. Zuchelli, Tobias McFarlin, Kellie Piraka, Cyrus Nimri, Faisal Arevalo-Mora, Martha Harris, Kevin Ashraf, Taha Denha, Eric Rahim, Ali Obri, Mark Gouda, Zane Bilello, Justin L. |
description | Gastric neurostimulation (GNS) and gastric peroral myotomy (G-POEM), therapies for refractory gastroparesis, are associated with suboptimal outcomes. We studied the role of G-POEM as a salvage therapy in patients with refractory symptoms after GNS implantation.
This was a multicenter, retrospective, matched case-control study. Consecutive patients with a GNS device and who underwent G-POEM as a salvage therapy for clinical failure (cases) and patients without GNS implantation and who underwent G-POEM for refractory gastroparesis (control) between October 2018 and August 2021 were included. The primary outcome was clinical success after G-POEM.
A total of 123 patients (mean age 45.7 ± 14.7 years; 88 female subjects [72%]) underwent G-POEM therapy during the study: 41 cases and 82 controls. Clinical success was achieved in 66% in the case group and 65% in the control group (P = .311), during a median total clinical follow-up time of 11.8 (interquartile range, 2.4-6.3) months. In the case group, the mean Gastroparesis Cardinal Symptom Index score decreased from 2.8 ± 1.8 to 1.5 ± 1.9 (P = .024), and gastric retention at 4 hours improved from 45% ± 25.8% to 16.6% ± 13.1% (P = .06). The mean delta improvement in the subscales of nausea/vomiting (1.3 ± .6 vs .9 ± 1.1, P = .044) and bloating (1.6 ± 1.3 vs 1.2 ± 1.4, P = .041) were significantly higher in cases than in controls.
Among patients with refractory symptoms after GNS, G-POEM can be a reasonable salvage therapy to provide further symptomatic relief with evidence of a potential additive effect of both G-POEM and GNS. |
doi_str_mv | 10.1016/j.gie.2023.04.2079 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2808217728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0016510723024938</els_id><sourcerecordid>2808217728</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-7f32c2deacf24dc9bf9a9c1a14f731cdcb1e88c3bfa59ccf9d18fa8532fafde3</originalsourceid><addsrcrecordid>eNp9UU1vEzEUtBCIpoU_wAH5yGWDP5J4F3FBFbRIlbj0bjnPz8HR7nqxvUH7p_obeVEKRy5-1nhm9DzD2Dsp1lLI3cfj-hBxrYTSa7GhaboXbCVFZ5qdMd1LthLEarZSmCt2XcpRCNEqLV-zK22kknq3WbGnO1dqjsAnzCm7nuPoU4E0ETQsqaZh4SFlPrjRHXDAsfIUeMaQHdSUF34469PkMpZYeBz55GokWuG_Y_15eSavEeecSo3D3DvScY-nCFg-cccJqnQfK2YyJrMyIdR4Qg6u0JFGwnpe6uyXN-xVcH3Bt8_zhj1--_p4e988_Lj7fvvloQG93dXGBK1AeXQQ1MZDtw-d60A6uQlGS_Cwl9i2oPfBbTuA0HnZBtdutQoueNQ37MPFdsrp14yl2iEWwL53I6a5WNVSktIY1RJVXahAixcKxk45Di4vVgp7rskeLdVkzzVZsbHnmkj0_tl_3g_o_0n-9kKEzxcC0idPEbMtQKkC-pgpHOtT_J__H8__q7A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2808217728</pqid></control><display><type>article</type><title>Gastric peroral endoscopic myotomy for management of refractory gastroparesis in patients with gastric neurostimulator devices: a multicenter retrospective case control study</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Ichkhanian, Yervant ; Al-Haddad, Mohammad A. ; Jacobs, Chelsea C. ; Schlachterman, Alexander ; Yang, Juliana ; Canakis, Andrew ; Kim, Raymond ; Guerson-Gil, Arcelia ; D’Souza, Lionel S. ; Alsheik, Eva ; Ginnebaugh, Brian D. ; Khashab, Mouen A. ; Zuchelli, Tobias ; McFarlin, Kellie ; Piraka, Cyrus ; Nimri, Faisal ; Arevalo-Mora, Martha ; Harris, Kevin ; Ashraf, Taha ; Denha, Eric ; Rahim, Ali ; Obri, Mark ; Gouda, Zane ; Bilello, Justin L.</creator><creatorcontrib>Ichkhanian, Yervant ; Al-Haddad, Mohammad A. ; Jacobs, Chelsea C. ; Schlachterman, Alexander ; Yang, Juliana ; Canakis, Andrew ; Kim, Raymond ; Guerson-Gil, Arcelia ; D’Souza, Lionel S. ; Alsheik, Eva ; Ginnebaugh, Brian D. ; Khashab, Mouen A. ; Zuchelli, Tobias ; McFarlin, Kellie ; Piraka, Cyrus ; Nimri, Faisal ; Arevalo-Mora, Martha ; Harris, Kevin ; Ashraf, Taha ; Denha, Eric ; Rahim, Ali ; Obri, Mark ; Gouda, Zane ; Bilello, Justin L. ; G-POEM study group ; G-POEM study-group</creatorcontrib><description>Gastric neurostimulation (GNS) and gastric peroral myotomy (G-POEM), therapies for refractory gastroparesis, are associated with suboptimal outcomes. We studied the role of G-POEM as a salvage therapy in patients with refractory symptoms after GNS implantation.
This was a multicenter, retrospective, matched case-control study. Consecutive patients with a GNS device and who underwent G-POEM as a salvage therapy for clinical failure (cases) and patients without GNS implantation and who underwent G-POEM for refractory gastroparesis (control) between October 2018 and August 2021 were included. The primary outcome was clinical success after G-POEM.
A total of 123 patients (mean age 45.7 ± 14.7 years; 88 female subjects [72%]) underwent G-POEM therapy during the study: 41 cases and 82 controls. Clinical success was achieved in 66% in the case group and 65% in the control group (P = .311), during a median total clinical follow-up time of 11.8 (interquartile range, 2.4-6.3) months. In the case group, the mean Gastroparesis Cardinal Symptom Index score decreased from 2.8 ± 1.8 to 1.5 ± 1.9 (P = .024), and gastric retention at 4 hours improved from 45% ± 25.8% to 16.6% ± 13.1% (P = .06). The mean delta improvement in the subscales of nausea/vomiting (1.3 ± .6 vs .9 ± 1.1, P = .044) and bloating (1.6 ± 1.3 vs 1.2 ± 1.4, P = .041) were significantly higher in cases than in controls.
Among patients with refractory symptoms after GNS, G-POEM can be a reasonable salvage therapy to provide further symptomatic relief with evidence of a potential additive effect of both G-POEM and GNS.</description><identifier>ISSN: 0016-5107</identifier><identifier>EISSN: 1097-6779</identifier><identifier>DOI: 10.1016/j.gie.2023.04.2079</identifier><identifier>PMID: 37121364</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Gastrointestinal endoscopy, 2023-10, Vol.98 (4), p.559-566.e1</ispartof><rights>2023 American Society for Gastrointestinal Endoscopy</rights><rights>Copyright © 2023 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-7f32c2deacf24dc9bf9a9c1a14f731cdcb1e88c3bfa59ccf9d18fa8532fafde3</citedby><cites>FETCH-LOGICAL-c356t-7f32c2deacf24dc9bf9a9c1a14f731cdcb1e88c3bfa59ccf9d18fa8532fafde3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0016510723024938$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37121364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ichkhanian, Yervant</creatorcontrib><creatorcontrib>Al-Haddad, Mohammad A.</creatorcontrib><creatorcontrib>Jacobs, Chelsea C.</creatorcontrib><creatorcontrib>Schlachterman, Alexander</creatorcontrib><creatorcontrib>Yang, Juliana</creatorcontrib><creatorcontrib>Canakis, Andrew</creatorcontrib><creatorcontrib>Kim, Raymond</creatorcontrib><creatorcontrib>Guerson-Gil, Arcelia</creatorcontrib><creatorcontrib>D’Souza, Lionel S.</creatorcontrib><creatorcontrib>Alsheik, Eva</creatorcontrib><creatorcontrib>Ginnebaugh, Brian D.</creatorcontrib><creatorcontrib>Khashab, Mouen A.</creatorcontrib><creatorcontrib>Zuchelli, Tobias</creatorcontrib><creatorcontrib>McFarlin, Kellie</creatorcontrib><creatorcontrib>Piraka, Cyrus</creatorcontrib><creatorcontrib>Nimri, Faisal</creatorcontrib><creatorcontrib>Arevalo-Mora, Martha</creatorcontrib><creatorcontrib>Harris, Kevin</creatorcontrib><creatorcontrib>Ashraf, Taha</creatorcontrib><creatorcontrib>Denha, Eric</creatorcontrib><creatorcontrib>Rahim, Ali</creatorcontrib><creatorcontrib>Obri, Mark</creatorcontrib><creatorcontrib>Gouda, Zane</creatorcontrib><creatorcontrib>Bilello, Justin L.</creatorcontrib><creatorcontrib>G-POEM study group</creatorcontrib><creatorcontrib>G-POEM study-group</creatorcontrib><title>Gastric peroral endoscopic myotomy for management of refractory gastroparesis in patients with gastric neurostimulator devices: a multicenter retrospective case control study</title><title>Gastrointestinal endoscopy</title><addtitle>Gastrointest Endosc</addtitle><description>Gastric neurostimulation (GNS) and gastric peroral myotomy (G-POEM), therapies for refractory gastroparesis, are associated with suboptimal outcomes. We studied the role of G-POEM as a salvage therapy in patients with refractory symptoms after GNS implantation.
This was a multicenter, retrospective, matched case-control study. Consecutive patients with a GNS device and who underwent G-POEM as a salvage therapy for clinical failure (cases) and patients without GNS implantation and who underwent G-POEM for refractory gastroparesis (control) between October 2018 and August 2021 were included. The primary outcome was clinical success after G-POEM.
A total of 123 patients (mean age 45.7 ± 14.7 years; 88 female subjects [72%]) underwent G-POEM therapy during the study: 41 cases and 82 controls. Clinical success was achieved in 66% in the case group and 65% in the control group (P = .311), during a median total clinical follow-up time of 11.8 (interquartile range, 2.4-6.3) months. In the case group, the mean Gastroparesis Cardinal Symptom Index score decreased from 2.8 ± 1.8 to 1.5 ± 1.9 (P = .024), and gastric retention at 4 hours improved from 45% ± 25.8% to 16.6% ± 13.1% (P = .06). The mean delta improvement in the subscales of nausea/vomiting (1.3 ± .6 vs .9 ± 1.1, P = .044) and bloating (1.6 ± 1.3 vs 1.2 ± 1.4, P = .041) were significantly higher in cases than in controls.
Among patients with refractory symptoms after GNS, G-POEM can be a reasonable salvage therapy to provide further symptomatic relief with evidence of a potential additive effect of both G-POEM and GNS.</description><issn>0016-5107</issn><issn>1097-6779</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9UU1vEzEUtBCIpoU_wAH5yGWDP5J4F3FBFbRIlbj0bjnPz8HR7nqxvUH7p_obeVEKRy5-1nhm9DzD2Dsp1lLI3cfj-hBxrYTSa7GhaboXbCVFZ5qdMd1LthLEarZSmCt2XcpRCNEqLV-zK22kknq3WbGnO1dqjsAnzCm7nuPoU4E0ETQsqaZh4SFlPrjRHXDAsfIUeMaQHdSUF34469PkMpZYeBz55GokWuG_Y_15eSavEeecSo3D3DvScY-nCFg-cccJqnQfK2YyJrMyIdR4Qg6u0JFGwnpe6uyXN-xVcH3Bt8_zhj1--_p4e988_Lj7fvvloQG93dXGBK1AeXQQ1MZDtw-d60A6uQlGS_Cwl9i2oPfBbTuA0HnZBtdutQoueNQ37MPFdsrp14yl2iEWwL53I6a5WNVSktIY1RJVXahAixcKxk45Di4vVgp7rskeLdVkzzVZsbHnmkj0_tl_3g_o_0n-9kKEzxcC0idPEbMtQKkC-pgpHOtT_J__H8__q7A</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Ichkhanian, Yervant</creator><creator>Al-Haddad, Mohammad A.</creator><creator>Jacobs, Chelsea C.</creator><creator>Schlachterman, Alexander</creator><creator>Yang, Juliana</creator><creator>Canakis, Andrew</creator><creator>Kim, Raymond</creator><creator>Guerson-Gil, Arcelia</creator><creator>D’Souza, Lionel S.</creator><creator>Alsheik, Eva</creator><creator>Ginnebaugh, Brian D.</creator><creator>Khashab, Mouen A.</creator><creator>Zuchelli, Tobias</creator><creator>McFarlin, Kellie</creator><creator>Piraka, Cyrus</creator><creator>Nimri, Faisal</creator><creator>Arevalo-Mora, Martha</creator><creator>Harris, Kevin</creator><creator>Ashraf, Taha</creator><creator>Denha, Eric</creator><creator>Rahim, Ali</creator><creator>Obri, Mark</creator><creator>Gouda, Zane</creator><creator>Bilello, Justin L.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231001</creationdate><title>Gastric peroral endoscopic myotomy for management of refractory gastroparesis in patients with gastric neurostimulator devices: a multicenter retrospective case control study</title><author>Ichkhanian, Yervant ; Al-Haddad, Mohammad A. ; Jacobs, Chelsea C. ; Schlachterman, Alexander ; Yang, Juliana ; Canakis, Andrew ; Kim, Raymond ; Guerson-Gil, Arcelia ; D’Souza, Lionel S. ; Alsheik, Eva ; Ginnebaugh, Brian D. ; Khashab, Mouen A. ; Zuchelli, Tobias ; McFarlin, Kellie ; Piraka, Cyrus ; Nimri, Faisal ; Arevalo-Mora, Martha ; Harris, Kevin ; Ashraf, Taha ; Denha, Eric ; Rahim, Ali ; Obri, Mark ; Gouda, Zane ; Bilello, Justin L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-7f32c2deacf24dc9bf9a9c1a14f731cdcb1e88c3bfa59ccf9d18fa8532fafde3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ichkhanian, Yervant</creatorcontrib><creatorcontrib>Al-Haddad, Mohammad A.</creatorcontrib><creatorcontrib>Jacobs, Chelsea C.</creatorcontrib><creatorcontrib>Schlachterman, Alexander</creatorcontrib><creatorcontrib>Yang, Juliana</creatorcontrib><creatorcontrib>Canakis, Andrew</creatorcontrib><creatorcontrib>Kim, Raymond</creatorcontrib><creatorcontrib>Guerson-Gil, Arcelia</creatorcontrib><creatorcontrib>D’Souza, Lionel S.</creatorcontrib><creatorcontrib>Alsheik, Eva</creatorcontrib><creatorcontrib>Ginnebaugh, Brian D.</creatorcontrib><creatorcontrib>Khashab, Mouen A.</creatorcontrib><creatorcontrib>Zuchelli, Tobias</creatorcontrib><creatorcontrib>McFarlin, Kellie</creatorcontrib><creatorcontrib>Piraka, Cyrus</creatorcontrib><creatorcontrib>Nimri, Faisal</creatorcontrib><creatorcontrib>Arevalo-Mora, Martha</creatorcontrib><creatorcontrib>Harris, Kevin</creatorcontrib><creatorcontrib>Ashraf, Taha</creatorcontrib><creatorcontrib>Denha, Eric</creatorcontrib><creatorcontrib>Rahim, Ali</creatorcontrib><creatorcontrib>Obri, Mark</creatorcontrib><creatorcontrib>Gouda, Zane</creatorcontrib><creatorcontrib>Bilello, Justin L.</creatorcontrib><creatorcontrib>G-POEM study group</creatorcontrib><creatorcontrib>G-POEM study-group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastrointestinal endoscopy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ichkhanian, Yervant</au><au>Al-Haddad, Mohammad A.</au><au>Jacobs, Chelsea C.</au><au>Schlachterman, Alexander</au><au>Yang, Juliana</au><au>Canakis, Andrew</au><au>Kim, Raymond</au><au>Guerson-Gil, Arcelia</au><au>D’Souza, Lionel S.</au><au>Alsheik, Eva</au><au>Ginnebaugh, Brian D.</au><au>Khashab, Mouen A.</au><au>Zuchelli, Tobias</au><au>McFarlin, Kellie</au><au>Piraka, Cyrus</au><au>Nimri, Faisal</au><au>Arevalo-Mora, Martha</au><au>Harris, Kevin</au><au>Ashraf, Taha</au><au>Denha, Eric</au><au>Rahim, Ali</au><au>Obri, Mark</au><au>Gouda, Zane</au><au>Bilello, Justin L.</au><aucorp>G-POEM study group</aucorp><aucorp>G-POEM study-group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastric peroral endoscopic myotomy for management of refractory gastroparesis in patients with gastric neurostimulator devices: a multicenter retrospective case control study</atitle><jtitle>Gastrointestinal endoscopy</jtitle><addtitle>Gastrointest Endosc</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>98</volume><issue>4</issue><spage>559</spage><epage>566.e1</epage><pages>559-566.e1</pages><issn>0016-5107</issn><eissn>1097-6779</eissn><abstract>Gastric neurostimulation (GNS) and gastric peroral myotomy (G-POEM), therapies for refractory gastroparesis, are associated with suboptimal outcomes. We studied the role of G-POEM as a salvage therapy in patients with refractory symptoms after GNS implantation.
This was a multicenter, retrospective, matched case-control study. Consecutive patients with a GNS device and who underwent G-POEM as a salvage therapy for clinical failure (cases) and patients without GNS implantation and who underwent G-POEM for refractory gastroparesis (control) between October 2018 and August 2021 were included. The primary outcome was clinical success after G-POEM.
A total of 123 patients (mean age 45.7 ± 14.7 years; 88 female subjects [72%]) underwent G-POEM therapy during the study: 41 cases and 82 controls. Clinical success was achieved in 66% in the case group and 65% in the control group (P = .311), during a median total clinical follow-up time of 11.8 (interquartile range, 2.4-6.3) months. In the case group, the mean Gastroparesis Cardinal Symptom Index score decreased from 2.8 ± 1.8 to 1.5 ± 1.9 (P = .024), and gastric retention at 4 hours improved from 45% ± 25.8% to 16.6% ± 13.1% (P = .06). The mean delta improvement in the subscales of nausea/vomiting (1.3 ± .6 vs .9 ± 1.1, P = .044) and bloating (1.6 ± 1.3 vs 1.2 ± 1.4, P = .041) were significantly higher in cases than in controls.
Among patients with refractory symptoms after GNS, G-POEM can be a reasonable salvage therapy to provide further symptomatic relief with evidence of a potential additive effect of both G-POEM and GNS.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37121364</pmid><doi>10.1016/j.gie.2023.04.2079</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0016-5107 |
ispartof | Gastrointestinal endoscopy, 2023-10, Vol.98 (4), p.559-566.e1 |
issn | 0016-5107 1097-6779 |
language | eng |
recordid | cdi_proquest_miscellaneous_2808217728 |
source | Elsevier ScienceDirect Journals Complete |
title | Gastric peroral endoscopic myotomy for management of refractory gastroparesis in patients with gastric neurostimulator devices: a multicenter retrospective case control study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A44%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastric%20peroral%20endoscopic%20myotomy%20for%20management%20of%20refractory%20gastroparesis%20in%20patients%20with%20gastric%20neurostimulator%20devices:%20a%20multicenter%20retrospective%20case%20control%20study&rft.jtitle=Gastrointestinal%20endoscopy&rft.au=Ichkhanian,%20Yervant&rft.aucorp=G-POEM%20study%20group&rft.date=2023-10-01&rft.volume=98&rft.issue=4&rft.spage=559&rft.epage=566.e1&rft.pages=559-566.e1&rft.issn=0016-5107&rft.eissn=1097-6779&rft_id=info:doi/10.1016/j.gie.2023.04.2079&rft_dat=%3Cproquest_cross%3E2808217728%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2808217728&rft_id=info:pmid/37121364&rft_els_id=S0016510723024938&rfr_iscdi=true |